CLB Valuation

Core Laboratories Inc

Add to Watchlist

Advanced Chart

10.460

+0.12(1.161%)1D

Overview
Forecast
Valuation
Earnings

CLB Relative Valuation

CLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLB is overvalued; if below, it's undervalued.

Historical Valuation

Core Laboratories Inc (CLB) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.09 is considered Undervalued compared with the five-year average of 27.03. The fair price of Core Laboratories Inc (CLB) is between 11.80 to 25.10 according to relative valuation methord. Compared to the current price of 10.46 USD , Core Laboratories Inc is Undervalued By 11.32%.

Relative Value

Fair Zone

11.80-25.10

Current Price：10.46

11.32%

Undervalued

13.09

Trailing

Forward

8.99

EV/EBITDA

Core Laboratories Inc. (CLB) has a current EV/EBITDA of 8.99. The 5-year average EV/EBITDA is 16.08. The thresholds are as follows: Strongly Undervalued below 6.34, Undervalued between 6.34 and 11.21, Fairly Valued between 20.95 and 11.21, Overvalued between 20.95 and 25.82, and Strongly Overvalued above 25.82. The current Forward EV/EBITDA of 8.99 falls within the Undervalued range.

11.85

EV/EBIT

Core Laboratories Inc. (CLB) has a current EV/EBIT of 11.85. The 5-year average EV/EBIT is 21.00. The thresholds are as follows: Strongly Undervalued below 6.29, Undervalued between 6.29 and 13.65, Fairly Valued between 28.36 and 13.65, Overvalued between 28.36 and 35.71, and Strongly Overvalued above 35.71. The current Forward EV/EBIT of 11.85 falls within the Undervalued range.

0.93

Core Laboratories Inc. (CLB) has a current PS of 0.93. The 5-year average PS is 2.01. The thresholds are as follows: Strongly Undervalued below 0.68, Undervalued between 0.68 and 1.34, Fairly Valued between 2.67 and 1.34, Overvalued between 2.67 and 3.33, and Strongly Overvalued above 3.33. The current Forward PS of 0.93 falls within the Undervalued range.

10.11

P/OCF

Core Laboratories Inc. (CLB) has a current P/OCF of 10.11. The 5-year average P/OCF is 19.42. The thresholds are as follows: Strongly Undervalued below 3.27, Undervalued between 3.27 and 11.34, Fairly Valued between 27.49 and 11.34, Overvalued between 27.49 and 35.57, and Strongly Overvalued above 35.57. The current Forward P/OCF of 10.11 falls within the Undervalued range.

12.56

P/FCF

Core Laboratories Inc. (CLB) has a current P/FCF of 12.56. The 5-year average P/FCF is 26.68. The thresholds are as follows: Strongly Undervalued below -2.30, Undervalued between -2.30 and 12.19, Fairly Valued between 41.17 and 12.19, Overvalued between 41.17 and 55.66, and Strongly Overvalued above 55.66. The current Forward P/FCF of 12.56 falls within the Historic Trend Line -Fairly Valued range.

Core Laboratories Inc (CLB) has a current Price-to-Book (P/B) ratio of 1.84. Compared to its 3-year average P/B ratio of 4.06 , the current P/B ratio is approximately -54.68% higher. Relative to its 5-year average P/B ratio of 6.83, the current P/B ratio is about -73.03% higher. Core Laboratories Inc (CLB) has a Forward Free Cash Flow (FCF) yield of approximately 8.03%. Compared to its 3-year average FCF yield of 2.96%, the current FCF yield is approximately 171.17% lower. Relative to its 5-year average FCF yield of 2.99% , the current FCF yield is about 168.41% lower.

1.84

P/B

Median3y

4.06

Median5y

6.83

8.03

FCF Yield

Median3y

2.96

Median5y

2.99

Competitors Valuation Multiple

The average P/S ratio for CLB's competitors is 0.89, providing a benchmark for relative valuation. Core Laboratories Inc Corp (CLB) exhibits a P/S ratio of 0.93, which is 4.85% above the industry average. Given its robust revenue growth of -0.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CLB.N

Core Laboratories Inc

Houston American Energy Corp

Loss

-4.53%

298.83M

Performance Decomposition

Market capitalization of CLB decreased by 46.50% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 7.04 to 8.20.

The secondary factor is the Revenue Growth, contributed -0.32%to the performance.

Overall, the performance of CLB in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-0.32%

130.58M → 130.16M

Revenue Growth

16.48%

7.04 → 8.20

Margin Expansion

-62.66%

44.64 → 16.67

P/E Change

-46.50%